Autologous CD19-targeted T cells

Chimeric antigen receptor T cells targeting CD19 · Memorial Sloan Kettering Cancer Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous CD19-targeted T cells, covering 2026-04-16 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 [Phase 1, Phase 2]

See pricing